Clavis, Clovis Sign $380 Million Partnership to Develop Anti-Cancer Agent

Clavis Pharma ASA … and Clovis Oncology, Inc., … announced an agreement for the further development and commercialization of the Clavis Pharma drug candidate, CP-4126, currently in Phase II development in pancreatic cancer.
Earth Times